Would you consider using tucatinib in a patient with de-novo metastatic HER2+ HR(-) breast cancer patient with extensive intraparenchymal and leptomeningeal carcinomatosis?
Are there other systemic therapy considerations to help achieve sufficient CNS control?
Answer from: Medical Oncologist at Academic Institution
Absolutely. The HER2CLIMB regimen is well known to have good CNS penetration. There is an ongoing trial looking at this regimen in Her2+ leptomeningeal disease (TBCRC049). Given the pacity of studied regimens/data in leptomeningeal disease, this is an excellent option. Other options include T Dx'd -...
Sign in or Register to read more